

**Summary:** A 16-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group, study of the analgesic effects of RN624 in adult patients with post-herpetic neuralgia (PHN)

**Inclusion Criteria:**

- Male or female patients aged  $\geq 18$  years
- Patients with a diagnosis of herpes zoster skin rash with pain for more than 3 months after healing
- Body Mass Index less than or equal to  $39 \text{ kg/m}^2$

**Exclusion Criteria:**

- Patients who have other moderate to severe pain that may confound assessments or self-evaluation of the pain associated with post herpetic neuralgia
- Pregnant or nursing (lactating) women
- Patients who suffer from skin conditions other than PHN, in the affected PHN area
- Use of opioids, muscle relaxants, topical analgesics, non-steroidal anti-inflammatory, or corticosteroids are prohibited during the clinical study
- Patients with the presence of alcohol, or drugs of abuse, other illicit drugs or marijuana in the urine toxicology screen obtained at first appointment visit
- Patient's with history of alcohol or drug abuse
- Patients who have had history or signs and symptoms of clinically significant cardiac disease within 3 months of screening
- Patients who have been treated with a shingles vaccine or any other live biologic vaccine within 3 months of the first appointment visit or any time during the study.
- Patients who have had treatment with investigational drugs at the time of enrollment, or within the last 30 days
- Any patient with active cancer or a history of cancer with less than 2 years disease free survival time

**Contact:**

Mary Kopp, RN, Clinical Research Coordinator

Telephone: 785-368-0743

Email: makopp@stormontvail.org